News

Looking at the Potential Impact of JCA on Pharma

April 02, 2024

The European pharma industry needs to be prepared for the new clinical data requirements.

Manufacturing Facility Updates

April 01, 2024

Pharmaceutical Technology gives a brief overview of some of developments in manufacturing facilities, including news from W.R. Grace & Co, ITT Inc, and SMC.

Amneal Pharmaceuticals Recalls Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 mL

March 30, 2024

The company is voluntarily recalling the product for potential super potent bottles due to overfilling.

J&J's Nipocalimab for FNAIT Gets on Fast Track for Approval

March 30, 2024

FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.

Dr. Reddy’s Partners with Sanofi Healthcare India to Distribute Vaccines

March 29, 2024

Dr. Reddy’s has gained exclusive rights to promote and distribute Sanofi’s vaccines in India.

Automation of Clinical Data Key in Meeting Cell and Gene Therapy Demand

March 29, 2024

Can Cellares deliver on the goal to meet total patient demand for cell therapies globally? CEO Fabian Gerlinghaus discusses.

AstraZeneca Gains FDA Nod for Ultomiris, a Treatment for Managing NMOSD

March 29, 2024

FDA has approved AstraZeneca's Ultomiris, marking the first and only long-acting C5 complement inhibitor for patients with NMOSD.

Univercells and Andelyn Biosciences Form Separate Drug Development Partnerships

March 28, 2024

Univercells and Altamira Therapeutics are collaborating on nanoparticle-delivered mRNA vaccines, while Andelyn Biosciences and Grace Science are partnering on novel therapies for NGLY1 deficiency.

AbbVie Gains Landos Biopharma and Full FDA Approval for ADC Product

March 28, 2024

The Landos acquisition adds a lead asset in autoimmune and inflammatory disease to AbbVie's portfolio, while the company's ADC, ELAHERE, gets full FDA approval.

Roche Sells Large-Scale Biologics Manufacturing Site in US to Lonza for $1.2 Billion

March 26, 2024

The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.